Le Domaine’s extremely innovative compound ProGR3® was created Progelife, a French biotech company founded by professor Nicolas Lévy, MD, PHD and Professor Pierre Cau, MD, PHD.
It is an original combination of natural molecules from plant extracts which targets Progerin, a mutated protein involved in 7 of the 9 mechanisms responsible of cell senescence and aging.
Progerine accumulates in skin cells (dermis, epidermis) and is detected on all skin types as of 2O years of age. It is a marker of natural skin aging for all of us.
In Progeria – a rare genetic disease that causes accelerated aging of childern - the accumulation of Progerine is considerably accelerated.
Professors Levy and Cau discovered in 2003 the mutation responsible of Progeria and Progelife has since then developed protocols to inhibate progerin prenylation and toxicity.
The identification of these mechanisms has allowed Progelife to create ProGr3®
(patent pending N°EP22315060.8)


GSM10® is based on more than 10 years of research by Professor Teissedre, PHD, on the grape varieties and marcs of the Perrin family and Chateau de Beaucastel vineyards. Made from a combination of marc from Grenache seeds, Syrah seeds and skins associated with a post-biotic micro-organism beneficial to the skin microbiome, this compound has impressively effective levels of antioxidants and anti-MMPs (matrix metallo-proteinases, uch as collagenase, which destroys collagen). In addition, GSM10® has been demonstrated to effectively balance the skin.
(patent pending N°EP22206512)

  • Nicolas Levy, MD, PHD

    - Professor in Medical Genetics (MD, PhD), Hospital Practitioner, Marseille

    - Director of Aix Marseille Université-INSERM Research Unit UMR_S1251 - "Marseille Medical Genetics"

    - Founder and first Director of the french Foundation for Rare DiseasesCSO Rare Diseases (Servier foundation)

  • Pierre Cau, MD, PHD

    - Professeur in Cell Biology (MD, PhD), Emeritus, former Hospital Practitioner, Marseille

    - Former Chief of Cell Biology Laboratory, La Timone Hospital, Marseille (1999-2013)

  • Eric Dussaud, PHD

    - PhD (Biology)

    - Degree in Statistics (CESAM, Fr)

    - More than 10 years experience in the field of therapeutic development for paediatric rare diseases

    - Clinical Project Manager for 6 years at Trophos company (International clinical trial for paediatric Amyotrophic lateral sclerosis)

  • Frédéric Beneton, Polytechnique

    - Ecole Polytechnique (X94), Master 2 in Physiology

    - 17 years experience in corporate and investment banking

    - 10 years experience in developing health startups

    - Co-founder of Bathysmed, Health-tech developing solutions against stress-linked diseases